Bleed risk 'outweighs benefits of aspirin' in prevention of CV events

The best strategy may be to simply prescribe a statin instead, says researcher

Three major trials of aspirin for primary prevention of cardiovascular events, viewed together, suggest its benefits are largely outweighed by the bleeding risk, a leading Harvard specialist says.


The results from the three studies should be considered in the context of findings from statin trials, according to Professor Paul Ridker, from the Centre for Cardiovascular Disease Prevention at the Brigham and Women’s Hospital in Boston.

“Beyond diet maintenance, exercise and smoking cessation, the best strategy for the use of aspirin in the primary